These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29573942)

  • 1. RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101.
    Wallis CJD; Klaassen Z
    Eur J Cancer; 2018 May; 94():216-217. PubMed ID: 29573942
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Parmar MKB; Tierney JF
    Eur J Cancer; 2018 May; 94():218-219. PubMed ID: 29548532
    [No Abstract]   [Full Text] [Related]  

  • 3. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Aggarwal R
    Eur Urol; 2018 Jun; 73(6):845-846. PubMed ID: 29128209
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
    Vale C; Fisher D; Tierney J; White I; Sydes M; Carpenter J
    Eur Urol; 2018 Mar; 73(3):e49-e50. PubMed ID: 29233663
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 7. External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. In Regard to Cho et al.
    Bhattacharyya T; Purushothaman K; Puthiyottil SS; Muttath G
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719. PubMed ID: 26461012
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy.
    Taneja SS
    J Urol; 2016 Nov; 196(5):1447. PubMed ID: 27751453
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002.
    Wallis CJD; Klaassen Z
    Eur Urol; 2018 Mar; 73(3):e51. PubMed ID: 29224912
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
    Hahn AW; Hale P; Rathi N; Agarwal N
    Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
    O'Cathail M; Sundar S
    Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improved survival in advanced or metastatic prostate cancer with initial androgen deprivation and concomitant abiraterone].
    Carl CO; Schwarz R; Petersen C
    Strahlenther Onkol; 2018 Mar; 194(3):266-268. PubMed ID: 29302703
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial Comment: Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Lott F
    Int Braz J Urol; 2021; 47(1):200-201. PubMed ID: 33047929
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM; Millett RL; Millado KF; Lin J
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abiraterone in castration resistant prostate cancer.].
    Juárez Soto A; Caballero Cobos R; Campanario Pérez R; Saiz Marenco R; Herrera Torres M; Gamaza Martínez R; Amores Bermúdez J
    Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
    Prescrire Int; 2014 Feb; 23(146):40-1. PubMed ID: 24669383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
    Griebling TL
    J Urol; 2020 Nov; 204(5):1073. PubMed ID: 32845185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.